Focusing on neurological conditions such as Parkinson’s disease, Multiple Sclerosis and other movement disorders, Magnes developed NUSHU smart shoes which perform gait analysis in real-time and gives biofeedback to patients to assist them while walking. Using smart sensors embedded in sneaker-type shoes, NUSHU collects data while the patient is walking or doing daily activities. AI-powered algorithms process the data to generate automatic reports.
NUSHU allows clinicians to perform patient assessments in a time and cost-effective way without the need for expensive laboratory-installed equipment. It can be used at the clinic as well as in remote settings, for example to monitor patients outside or at home. By integrating NUSHU into clinical practice, Magnes is striving to empower medical practitioners with the tools they need to offer personalized and effective disease management and rehabilitation programs. Patients can also benefit from Magnes’ unique solution, NUSHU. It is the only solution that can analyze gait in real-time and give direct vibrotactile biofeedback to patients based on their gait (video example).
The FDA Clearance announced early this weekend paved the way for the company’s entry in to the US market, where NUSHU is currently being marketed. Now with the CE certification, Magnes is set to offer its solution to patients and clinicians in Europe. NUSHU smart shoes can be utilized to address the needs of millions of neurological patients in Europe.
Olgaç Ergeneman, CEO of Magnes commented, “Receiving this CE certification is an important milestone for our company. We are fully dedicated to supporting neurological patients worldwide and making technological solutions such as NUSHU accessible to all patients. We will continue our research and development activities to deliver innovative solutions to address the challenges faced daily by patients. With our solutions, we will help patients to manage their conditions better and increase their quality of life.”
(Press release/RAN)